Stem cell engineering transformation method based on polydopamine and VCAM1 antibody and application of stem cell engineering transformation method
By modifying the double-stranded DNA fragments and VCAM1 antibody conjugates on the surface of stem cells to bind polydopamine nanoparticles, the problem of low stem cell retention and survival is solved, and more efficient tissue repair is achieved, and the method is simple and safe.
Patent Information
- Application Number
- CN202410783751.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-13
- Filing Date
- 2024-06-18
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-06-18
AI Technical Summary
The retention and survival rate of stem cells in clinical treatment are low, resulting in poor treatment results. The existing modification methods are complex, time-consuming and safety risks.
By modifying particles and adhesion molecules that remove reactive oxygen species on the surface of stem cells, using double-stranded DNA fragments and VCAM1 antibody conjugates to combine polydopamine nanoparticles, the adhesion ability and survival rate of stem cells is improved, and a simple and safe engineering transformation method is adopted. .
It significantly improves the retention and survival rate of stem cells in damaged tissues, enhances its repair ability, and is simple to operate and safe, and is suitable for a variety of stem cell types.
Smart Images

Figure CN118910039A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to a stem cell engineering transformation method based on polydopamine and VCAM1 antibody and an application thereof. Background Art
[0002] Stem cells have a variety of unique properties and capabilities, including sustained high self-renewal activity, multi-lineage differentiation ability, host repopulation and secretion of restorative paracrine factors, which make them an ideal cell source for cell therapy, regenerative medicine and tissue engineering. Transplanted stem cells mainly improve the microenvironment of damaged tissues through paracrine pathways, exert their therapeutic functions, and show extremely high application value in the treatment of major diseases such as tissue damage. However, studies have shown that the retention rate of transplanted stem cells in damaged tissues is extremely poor. The proportion of transplanted cells that successfully colonize in damaged tissues by intravenous delivery is usually less than 1%. Even if they are delivered to the damaged site by local injection, the cells are still easy to spread, and the proportion of cells that can successfully colonize in damaged tissues is usually less than 5%. On the other hand, the survival rate of transplanted stem cells in damaged tissues is extremely low. Studies have found that most of the stem cells transplanted to the damaged myocardium die within 1 week, and the survival rate within 4-6 weeks is only about 1%. The low retention rate and low survival rate of transplanted stem cells seriously restrict their clinical efficacy. Summary of the invention
[0003] The technical problem to be solved by the present invention is to overcome the deficiencies and defects of stem cells in clinical treatment mentioned in the above-mentioned prior art, and provide a new stem cell engineering modification method, which modifies the surface of stem cells with particles and adhesion molecules that remove reactive oxygen species. The engineering modification method is simple to operate and has little effect on cells. The prepared engineered stem cells can be more efficiently retained and survive in damaged tissues than unmodified stem cells, and then better repair damaged tissues.
[0004] To this end, the present invention provides a double-stranded DNA fragment.
[0005] The present invention also provides a VCAM1 antibody conjugate.
[0006] The present invention also provides a cell.
[0007] The present invention also provides a kit.
[0008] The present invention also provides the application of the double-stranded DNA fragment, VCAM1 antibody conjugate, polydopamine nanoparticle or kit.
[0009] The invention also provides a cell engineering transformation method.
[0010] The present invention also proposes the application of the above-mentioned cell or cell engineering transformation method.
[0011] According to a first aspect of the present invention, a double-stranded DNA fragment is provided, wherein the double-stranded DNA fragment comprises a DNA monomer 1 and a DNA monomer 2; the nucleotide sequence of the DNA monomer 1 is as shown in SEQ ID NO:1; the nucleotide sequence of the DNA monomer 2 is as shown in SEQ ID NO:2; the nucleotide sequences of the DNA monomer 1 and the DNA monomer 2 are complementary.
[0012] In some embodiments of the present invention, the 5' end of the nucleotide sequence of the DNA monomer 1 is connected to an NH2C6 group.
[0013] In some embodiments of the present invention, a cholesterol group is connected to the 5' end of the nucleotide sequence of the DNA monomer 2.
[0014] According to a second aspect of the present invention, a VCAM1 antibody conjugate is provided, wherein the VCAM1 antibody conjugate comprises a VCAM1 antibody and a polymer connected by a covalent bond; the polymer comprises at least one of the double-stranded DNA fragment described in the first aspect of the present invention, DSPE-PEG-NHS, DMPE-PEG-NHS and DOPE-PEG-NHS;
[0015] In some embodiments of the present invention, the method for preparing the VCAM1 antibody conjugate comprises the following steps:
[0016] A1: DNA monomer 1 and cross-linking agent 1 are mixed and reacted to obtain DNA monomer 1-cross-linking agent 1;
[0017] A2: VCAM1 antibody and cross-linker 2 are mixed and reacted to obtain VCAM1 antibody-cross-linker 2;
[0018] A3: mixing the DNA monomer 1-crosslinker 1 described in step A1 with the VCAM1 antibody-crosslinker 2 described in step A2 to obtain a VCAM1 antibody-DNA monomer 1 covalent conjugate;
[0019] A4: The VCAM1 antibody-DNA monomer 1 covalent conjugate described in step A3 is mixed with the DNA monomer 2 to react to obtain a VCAM1 antibody conjugate.
[0020] In some preferred embodiments of the present invention, the cross-linking agent 1 in step A1 includes at least one of succinimidyl-4-formylbenzoate (S-4FB), NHS-PEG-Azide, NHS-PEG-DBCO and NHS-PEG-BCN.
[0021] In some more preferred embodiments of the present invention, the cross-linking agent 1 in step A1 is S-4FB.
[0022] In some more preferred embodiments of the present invention, the NH2C6 group of the DNA monomer 1 in step A1 is connected to S-4FB.
[0023] In some preferred embodiments of the present invention, the reaction temperature in step A1 is 20°C to 37°C.
[0024] In some more preferred embodiments of the present invention, the reaction temperature in step A1 is 25°C.
[0025] In some preferred embodiments of the present invention, the reaction time in step A1 is 1 to 3 hours.
[0026] In some more preferred embodiments of the present invention, the reaction time in step A1 is 2 hours.
[0027] In some preferred embodiments of the present invention, the reaction in step A1 is carried out under an oscillation reaction at a rotation speed of 300 to 500 rpm.
[0028] In some more preferred embodiments of the present invention, the reaction in step A1 is carried out under an oscillation reaction at a rotation speed of 400 rpm.
[0029] In some preferred embodiments of the present invention, the cross-linking agent 2 in step A2 includes at least one of succinimidyl-6-hydrazinonicotinic acid acetone hydrazone (S-HyNic), NHS-PEG-Azide, NHS-PEG-DBCO and NHS-PEG-BCN.
[0030] In some more preferred embodiments of the present invention, the cross-linking agent 2 in step A2 is S-HyNic.
[0031] In some preferred embodiments of the present invention, the reaction temperature in step A2 is 20°C to 37°C.
[0032] In some more preferred embodiments of the present invention, the reaction temperature in step A2 is 25°C.
[0033] In some preferred embodiments of the present invention, the reaction time in step A2 is 1 to 3 hours.
[0034] In some more preferred embodiments of the present invention, the reaction time in step A2 is 2 hours.
[0035] In some preferred embodiments of the present invention, the reaction in step A2 is carried out under an oscillation reaction at a rotation speed of 300 to 500 rpm.
[0036] In some more preferred embodiments of the present invention, the reaction in step A2 is carried out under an oscillation reaction at a rotation speed of 400 rpm.
[0037] In some preferred embodiments of the present invention, the reaction in step A3 is a covalent linking reaction of S-HyNic and S-4FB.
[0038] In some preferred embodiments of the present invention, the reaction temperature in step A3 is 20°C to 37°C.
[0039] In some more preferred embodiments of the present invention, the reaction temperature in step A3 is 25°C.
[0040] In some preferred embodiments of the present invention, the reaction time in step A3 is 1 to 3 hours.
[0041] In some more preferred embodiments of the present invention, the reaction time in step A3 is 2 hours.
[0042] In some preferred embodiments of the present invention, the reaction in step A3 is carried out under an oscillation reaction at a rotation speed of 300 to 500 rpm.
[0043] In some more preferred embodiments of the present invention, the reaction in step A3 is carried out under an oscillation reaction at a rotation speed of 400 rpm.
[0044] In some preferred embodiments of the present invention, the reaction in step A4 is a base complementary pairing reaction between DNA monomer 1 and DNA monomer 2.
[0045] In some preferred embodiments of the present invention, the reaction temperature in step A4 is 20°C to 37°C.
[0046] In some more preferred embodiments of the present invention, the reaction temperature in step A4 is 25°C.
[0047] In some preferred embodiments of the present invention, the reaction time in step A4 is 10 to 50 minutes.
[0048] In some more preferred embodiments of the present invention, the reaction time in step A4 is 30 min.
[0049] In some preferred embodiments of the present invention, the reaction in step A4 is carried out under an oscillation reaction at a rotation speed of 400 to 600 rpm.
[0050] In some more preferred embodiments of the present invention, the reaction in step A4 is carried out under an oscillation reaction at a rotation speed of 500 rpm.
[0051] According to the third aspect of the present invention, a cell is provided, the surface of which is modified with: the VCAM1 antibody conjugate and polydopamine nanoparticles as described in the second aspect of the present invention.
[0052] In some embodiments of the present invention, the polydopamine nanoparticles are dopamine monomers in a Ca-containing 2+ polymerized in an alkaline buffer.
[0053] In some preferred embodiments of the present invention, the alkaline buffer comprises Tris-HCl buffer.
[0054] In some preferred embodiments of the present invention, the pH value of the alkaline buffer solution is 7.8-8.8.
[0055] In some more preferred embodiments of the present invention, the pH value of the alkaline buffer is 8.35.
[0056] In some preferred embodiments of the present invention, the Ca in the alkaline buffer is 2+ The content is 0.11~4.44wt%.
[0057] In some more preferred embodiments of the present invention, the Ca in the alkaline buffer is 2+ The content is 1.11wt%.
[0058] In some preferred embodiments of the present invention, the concentration of the dopamine monomer in the alkaline buffer is 0.05-5 mg / mL.
[0059] In some more preferred embodiments of the present invention, the concentration of the dopamine monomer in the alkaline buffer is 2 mg / mL.
[0060] In some embodiments of the invention, the cells comprise stem cells.
[0061] In some preferred embodiments of the present invention, the stem cells include mesenchymal stem cells.
[0062] According to a fourth aspect of the present invention, a kit is provided, comprising:
[0063] (1) the VCAM1 antibody conjugate according to the second aspect of the present invention; and
[0064] (2) The polydopamine nanoparticles as described in the third aspect of the present invention.
[0065] According to the fifth aspect of the present invention, a use of the double-stranded DNA fragment as described in the first aspect of the present invention, the VCAM1 antibody conjugate as described in the second aspect of the present invention, the polydopamine nanoparticles as described in the third aspect of the present invention or the kit as described in the fourth aspect of the present invention in cell engineering transformation is proposed.
[0066] In some embodiments of the invention, the cells comprise stem cells.
[0067] In some preferred embodiments of the present invention, the stem cells include mesenchymal stem cells.
[0068] According to a sixth aspect of the present invention, a cell engineering modification method is provided, the cell engineering modification method comprising the following steps:
[0069] S1: mixing the cells to be modified with the dopamine monomers described in the third aspect of the present invention to react and obtain cells modified with polydopamine nanoparticles;
[0070] S2: Mixing the cells modified with the polydopamine nanoparticles described in step S1 with the VCAM1 antibody conjugate described in the second aspect of the present invention, and reacting to obtain engineered cells.
[0071] In some embodiments of the present invention, the cells to be transformed in step S1 include stem cells.
[0072] In some preferred embodiments of the present invention, the stem cells include mesenchymal stem cells.
[0073] In some embodiments of the present invention, the final concentration of the dopamine monomer in step S1 is 0.05-5 mg / mL.
[0074] In some preferred embodiments of the present invention, the final concentration of the dopamine monomer in step S1 is 2 mg / mL.
[0075] In some embodiments of the present invention, the cells to be modified in step S1 are mixed with dopamine monomers in a Ca-containing 2+ react in an alkaline buffer.
[0076] In some preferred embodiments of the present invention, the alkaline buffer is Tris-HCl buffer.
[0077] In some more preferred embodiments of the present invention, the concentration of the Tris-HCl buffer is 10 mM.
[0078] In some preferred embodiments of the present invention, the pH value of the alkaline buffer solution is 7.8-8.8.
[0079] In some more preferred embodiments of the present invention, the pH value of the alkaline buffer is 8.35.
[0080] In some preferred embodiments of the present invention, the Ca in the alkaline buffer is 2+ The content is 0.11~4.44wt%.
[0081] In some more preferred embodiments of the present invention, the Ca in the alkaline buffer is 2+ The content is 1.11wt%.
[0082] In some embodiments of the present invention, the reaction temperature in step S1 is 20-37°C.
[0083] In some preferred embodiments of the present invention, the reaction temperature in step S1 is 25°C.
[0084] In some embodiments of the present invention, the reaction time in step S1 is 5 to 15 minutes.
[0085] In some preferred embodiments of the present invention, the reaction time in step S1 is 8 minutes.
[0086] In some embodiments of the present invention, the reaction in step S1 is an oscillation reaction at a rotation speed of 400 to 600 rpm.
[0087] In some preferred embodiments of the present invention, the reaction in step S1 is an oscillation reaction at a rotation speed of 500 rpm.
[0088] In some embodiments of the present invention, the density of the cells to be transformed in the reaction system in step S1 is 5×10 5 ~1.5×10 6 Pieces / mL.
[0089] In some preferred embodiments of the present invention, the density of the cells to be transformed in the reaction system in step S1 is 1×10 6 Pieces / mL.
[0090] In some embodiments of the present invention, the density of the polydopamine nanoparticle-modified cells in the reaction system in step S2 is 3×10 6 ~7×10 6 Pieces / mL.
[0091] In some preferred embodiments of the present invention, the density of the polydopamine nanoparticle-modified cells in the reaction system in step S2 is 5×10 6 Pieces / mL.
[0092] In some embodiments of the present invention, the final concentration of the VCAM1 antibody conjugate in the reaction system in step S2 is 0.5-1.5 μM.
[0093] In some preferred embodiments of the present invention, the final concentration of the VCAM1 antibody conjugate in the reaction system in step S2 is 1 μM.
[0094] In some embodiments of the present invention, the reaction temperature in step S2 is 20-37°C.
[0095] In some preferred embodiments of the present invention, the reaction temperature in step S2 is 25°C.
[0096] In some embodiments of the present invention, the reaction time of step S2 is 15 to 60 minutes.
[0097] In some preferred embodiments of the present invention, the reaction time in step S2 is 30 minutes.
[0098] In some embodiments of the present invention, the reaction in step S2 is an oscillation reaction at a rotation speed of 400-600 rpm.
[0099] In some preferred embodiments of the present invention, the reaction in step S2 is an oscillation reaction at a rotation speed of 500 rpm.
[0100] According to the seventh aspect of the present invention, the use of the cell according to the third aspect of the present invention or the cell engineering transformation method according to the sixth aspect of the present invention in at least one of (1) to (3) is provided:
[0101] (1) Preparation of products for tissue repair;
[0102] (2) Preparation of products for enhancing the retention of cells in damaged tissues;
[0103] (3) Prepare products for enhancing the survival ability of cells in damaged tissues.
[0104] In some embodiments of the present invention, the product comprises a medicine or a health product.
[0105] In some preferred embodiments of the present invention, the dosage form of the drug is a liquid dosage form.
[0106] In some embodiments of the invention, the cells comprise stem cells.
[0107] In some preferred embodiments of the present invention, the stem cells include mesenchymal stem cells.
[0108] The present invention has at least the following beneficial effects:
[0109] (1) The double-stranded DNA fragment provided by the present invention comprises a pair of DNAs with complementary sequences (DNA monomer 1 and DNA monomer 2). The double-stranded DNA fragment is designed with a DNA sequence that meets the requirements by utilizing the programmability of DNA. The VCAM1 antibody can be modified on the surface of stem cells by using the DNA fragment, thereby improving the adhesion ability of stem cells to damaged tissues, thereby promoting tissue repair;
[0110] (2) The VCAM1 antibody conjugate provided by the present invention can be modified on the surface of stem cells, thereby improving the adhesion ability of stem cells, allowing them to reside in the damaged tissue for a long time and better play a repair role;
[0111] (3) The polydopamine nanoparticles provided by the present invention are formed by spontaneous polymerization of dopamine monomers in an alkaline buffer solution. The polydopamine nanoparticles are prepared by Ca 2+ The bridging effect of the glycosides on the surface of stem cells enhances the resistance of stem cells to reactive oxygen species in damaged tissues, thereby increasing the survival rate of stem cells in damaged tissues and promoting tissue repair.
[0112] (4) The cells provided by the present invention are engineered cells whose surfaces are modified with the above-mentioned VCAM1 antibody conjugate and polydopamine nanoparticles. Through the modification of the above-mentioned functional molecules, the retention rate and survival rate of stem cells in damaged tissues can be improved at the same time without affecting the vitality and migration ability of stem cells;
[0113] (5) The stem cell engineering transformation method proposed in the present invention only requires that the cells to be transformed be combined with dopamine monomers in a Ca-containing 2+ The invention relates to a method for preparing an engineered stem cell. The method comprises mixing the DNA monomer 1 with an alkaline buffer solution to allow the dopamine monomer to self-polymerize on the cell surface; then connecting the DNA monomer 1 with the VCAM1 antibody; finally, mixing the DNA monomer 1-VCAM1 antibody covalent conjugate, the DNA monomer 2 and the cells modified with polydopamine nanoparticles, and connecting the VCAM1 antibody to the cell surface by using a DNA hybridization chain reaction, thereby obtaining an engineered stem cell. Compared with the existing stem cell transformation method, the stem cell engineering transformation method provided by the invention is simple to operate, short in time, high in transformation efficiency, free of safety risks, and has a wide range of administration routes, and can effectively improve the retention rate and survival rate of stem cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0114] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:
[0115] Figure 1 This is a schematic diagram of the process of the stem cell engineering transformation method in Example 1 of the present invention;
[0116] Figure 2The scanning electron microscopy results of the control group cells and the polydopamine-modified group mesenchymal stem cells in Example 1 of the present invention, wherein the scale bar is 2 μm;
[0117] Figure 3 The transmission electron microscopy results of the control group cells and the polydopamine-modified group mesenchymal stem cells in Example 1 of the present invention are shown, wherein the scale bar is 2 μm;
[0118] Figure 4 This is a diagram showing the SDS-PAGE electrophoresis result of the VCAM1 antibody and the DNA1-VCAM1 antibody covalent conjugate in Example 1 of the present invention;
[0119] Figure 5 The flow cytometry results of affinity binding of the VCAM1 antibody and the DNA1-VCAM1 antibody covalent conjugate to K562 and C166 cells in Example 1 of the present invention are shown; wherein A and B are the flow cytometry histogram and the FITC channel fluorescence intensity statistical graph, respectively;
[0120] Figure 6 This is a flow cytometry result diagram of mesenchymal stem cells in the control group, the polydopamine modified group and the polydopamine-VCAM1 antibody modified group in Example 1 of the present invention;
[0121] Figure 7 This is a laser confocal image of mesenchymal stem cells modified with polydopamine and VCAM1 antibody in Example 1 of the present invention, wherein the scale bar is 25 μm;
[0122] Figure 8 The scanning electron microscopy results of the control group cells and the polydopamine modified group embryonic stem cells in Example 2 of the present invention, wherein the scale bar is 2 μm;
[0123] Fig. 9 This is a laser confocal image of embryonic stem cells modified with polydopamine and VCAM1 antibody in Example 2 of the present invention, wherein the scale bar is 25 μm;
[0124] Fig.10 This is a flow cytometry graph of apoptosis of mesenchymal stem cells in the control group, the polydopamine modified group, and the polydopamine and VCAM1 antibody co-modified group in the test examples of the present invention;
[0125] Fig.11 The figure is a migration detection diagram of the control group and the engineered transformation group of mesenchymal stem cells in the test example of the present invention; wherein A is a microscopic photograph of the mesenchymal stem cells of each group after migration, wherein the scale bar is 100 μm, and B is a statistical diagram of the number of cells migrating in each group;
[0126] Fig.12 It is a statistical graph of the paracrine factor content of mesenchymal stem cells in the control group and the engineered transformation group in the test example of the present invention;
[0127] Fig.13 The fluorescence imaging diagram of intracellular reactive oxygen species in the control group and the polydopamine-modified group of mesenchymal stem cells treated with hydrogen peroxide in the experimental example of the present invention, wherein the scale bar is 50 μm;
[0128] Fig.14 This is a graph showing the results of detecting the cell viability of the control group and the engineered transformation group of mesenchymal stem cells under treatment with different concentrations of hydrogen peroxide using the CCK8 method in the test example of the present invention; wherein, "ns" represents no significant difference, and "***" represents p < 0.001;
[0129] Fig.15 Live-dead fluorescence imaging of mesenchymal stem cells in the control group and the engineered group treated with different concentrations of hydrogen peroxide;
[0130] Fig.16 The graphs are the results of the adhesion of mesenchymal stem cells to C166 cells in the control group and the engineered transformation group in the test examples of the present invention; wherein A is the fluorescence imaging picture of the adhesion of mesenchymal stem cells to C166 cells in the control group and the engineered transformation group, and the scale bar is 100 μm; B is the statistical graph of the number of mesenchymal stem cells adhering to C166 cells in each group;
[0131] Fig.17 This is a schematic diagram of the process of establishing a rat myocardial infarction model and injecting cells into the myocardium in the test example of the present invention;
[0132] Fig.18 The figure is a graph showing the retention and survival results of the mesenchymal stem cells in the control group and the engineered transformation group three days after the mesenchymal stem cells were injected into the infarcted myocardium of the rats in the test example of the present invention; wherein A is a live imaging graph of the mesenchymal stem cells in the control group and the engineered transformation group in the infarcted myocardium of the rats; and B is a statistical graph of the bioluminescence intensity of the mesenchymal stem cells in the infarcted myocardium of the rats in each group;
[0133] Fig.19 The results of the engineered mesenchymal stem cells in the test example of the present invention restoring the cardiac function of the infarcted heart of the rats; wherein A is the cardiac ultrasound image of the rats in each group after 28 days of treatment; B is the statistical graph of the left ventricular ejection fraction of the hearts of each group; C is the statistical graph of the left ventricular shortening fraction of the hearts of each group;
[0134] Fig. 20 The figures are the results of the engineered mesenchymal stem cells repairing the infarcted myocardium of rats in the test examples of the present invention; wherein A is the Masson's trichrome staining of the heart tissue sections of each group after 28 days of treatment; B is the statistical diagram of the infarcted area size in the myocardial tissue sections of each group; C is the statistical diagram of the left ventricular wall thickness in the myocardial tissue sections of each group;
[0135] Fig.21The figure is a fluorescence imaging diagram of reactive oxygen species in myocardial tissue of rats with infarcted myocardium treated with engineered mesenchymal stem cells for three days in the test example of the present invention; wherein A is a fluorescence imaging diagram of reactive oxygen species in heart slices of each group, with a scale of 100 μm; and B is a statistical diagram of the fluorescence intensity of reactive oxygen species in heart slices of each group;
[0136] Fig. 22 The CD31 vascular immunofluorescence staining images after the engineered mesenchymal stem cells repaired the infarcted myocardium of rats in the test example of the present invention; wherein A is the CD31 vascular fluorescence imaging image of the heart slices of each group after 28 days of treatment, and the scale bar is 100 μm; B is a statistical graph of the number of CD31 blood vessels in the heart slices of each group;
[0137] Fig.23 These are α-SMA vascular immunofluorescence staining images of the engineered mesenchymal stem cells repairing the infarcted myocardium of rats in the test example of the present invention; wherein A is the α-SMA vascular fluorescence imaging image of the heart slices of each group after 28 days of treatment, with a scale of 100 μm; and B is a statistical graph of the number of α-SMA blood vessels in the heart slices of each group. DETAILED DESCRIPTION
[0138] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0139] Example 1
[0140] This embodiment provides a stem cell engineering transformation method, and according to the method, an engineered mesenchymal stem cell is prepared. The flow chart of the stem cell engineering transformation method is as follows: Figure 1 As shown, the specific steps include:
[0141] 1. Preparation of mesenchymal stem cells modified with polydopamine nanoparticles:
[0142] (1) Take 4 mL of 1 M CaCl2 and 0.4 mL of 1 M Tris-HCl solution and dissolve them in 35 mL of deionized water. Use 0.1 M NaOH solution to adjust the pH to 8.35 to obtain Tris-HCl alkaline buffer solution. The concentration of Tris-HCl is 10 mM, and the Ca content of the alkaline buffer solution is 10 mM. 2+ The content is 1.11wt%;
[0143] (2) Weigh 10 mg of dopamine hydrochloride and dissolve it in 50 μL of Tris-HCl alkaline buffer prepared in step (1) to prepare a dopamine hydrochloride solution with a concentration of 200 mg / mL;
[0144] (3) Take 990 μL of Tris-HCl alkaline buffer and add it to a 1×10 6 EP tubes containing rat bone marrow-derived mesenchymal stem cells were added to obtain a cell suspension; then 10 μL of the dopamine hydrochloride solution prepared in step (2) was added to the cell suspension, and the cells were gently blown 5 times with a pipette to make the cells uniform;
[0145] (4) Transfer the uniformly dispersed cell suspension in step (3) to a shaking metal bath and shake at 500 rpm for 8 min at 25°C, gently blowing 1 to 2 times with a pipette;
[0146] (5) After the reaction is completed, the cell suspension is taken out, centrifuged at 300 g for 5 min, and the supernatant is removed to obtain a cell pellet;
[0147] (6) Add 1 mL of 1×PBS to the cell pellet obtained by centrifugation in step (5) to resuspend the cells, centrifuge again at 300 g for 5 min, and remove the supernatant to prepare polydopamine nanoparticle-modified mesenchymal stem cells.
[0148] The mesenchymal stem cells modified with polydopamine nanoparticles prepared in step 1 were characterized by scanning electron microscopy and transmission electron microscopy. The results were as follows: Figure 2 (SEM) and Figure 3 (Transmission electron microscopy). The control group cells are unmodified mesenchymal stem cells.
[0149] Depend on Figure 2-Figure 3 It can be seen that the cell surface of the control group is relatively smooth, while the surface of the mesenchymal stem cells modified with polydopamine nanoparticles is rough, and obvious nanoparticles can be seen, indicating that the present invention successfully modifies the surface of mesenchymal stem cells with polydopamine.
[0150] 2. Covalently link DNA monomer 1 and VCAM1 antibody:
[0151] (1) The nucleotide sequence of DNA monomer 1 covalently coupled to the VCAM1 antibody is: 5'-GGTAAACA AAGGCTGCTCCAGAAGCAGCCTTTGTTTACCGATTAGC-3' (SEQ ID NO: 1), and an NH2C6 group is connected to the 5' end. The DNA monomer 1 was synthesized by Sangon Biotech (Shanghai) Co., Ltd. In the subsequent steps, the DNA monomer 1 is referred to as DNA1;
[0152] (2) DNA1 is linked to succinimidyl-4-formylbenzoate (S-4FB):
[0153] ① 30 nmol DNA1 was vortexed and dissolved in 60 μL Buffer M (i.e., 1×PBS, pH 8.0) to prepare a DNA1 solution; then the DNA1 solution was annealed by a PCR instrument, and the annealing program was 95°C for 5 min, 84°C for 2 min, 73°C for 2 min, 62°C for 2 min, 51°C for 2 min, 40°C for 2 min, 30°C for 2 min, and 25°C for 2 min;
[0154] ② Dissolve 1 mg of S-4FB (Solulink, catalog number S-1004-010) in 40 μL of anhydrous dimethyl sulfoxide (DMSO) to prepare a 25 mg / mL S-4FB solution; add 30 μL of anhydrous DMSO and 7.2 μL of S-4FB solution to the annealed DNA1 solution, vortex to mix evenly, and shake at 400 rpm at 25°C for 2 h;
[0155] ③ After the reaction is completed, the reaction mixture is transferred to a 10kDa ultrafiltration tube, 400μL of Buffer C (i.e., 1×PBS with pH 6.0) is added, centrifuged at 13000g for 10min, the waste liquid is discarded, and this process is repeated 4 times; then the ultrafiltration tube is inverted and placed in a new centrifuge tube, centrifuged at 1300g for 3min, and the collected DNA1-S-4FB is fixed to 100μL with Buffer C to obtain a DNA1-S-4FB solution;
[0156] (3) VCAM1 antibody is linked to succinimidyl-6-hydrazinonicotinic acid acetone hydrazone (S-HyNic):
[0157] ① Transfer 100 μg of VCAM1 antibody (Biolegend, catalog number 105728) to a 10 kDa ultrafiltration tube, add Buffer M to make the total volume 500 μL, centrifuge at 13000 g for 10 min, and discard the waste liquid; add Buffer M again to make the total volume 500 μL, centrifuge at 13000 g for 10 min, and discard the waste liquid; then invert the ultrafiltration tube into a new centrifuge tube, centrifuge at 1300 g for 3 min, and use Buffer M to make the collected VCAM1 antibody volume 100 μL to obtain a VCAM1 antibody solution;
[0158] ② Dissolve 100 μg of S-HyNic (Solulink, catalog number S-1002-105) in 35 μL of anhydrous DMSO to prepare a 2.86 mg / mL S-HyNic solution, add 3 μL of the S-HyNic solution to the above VCAM1 antibody solution, mix well by pipetting to obtain a VCAM1 antibody mixed solution, and shake at 400 rpm at 25°C for 2 h;
[0159] ③ After the reaction is completed, transfer the VCAM1 antibody mixed solution to a 30kDa ultrafiltration tube, add Buffer C to make the total volume 500μL, centrifuge at 13000g for 10min, discard the waste liquid, and repeat this washing process 3 times; then turn the ultrafiltration tube upside down in a new centrifuge tube, centrifuge at 1500g for 3min, and use Buffer C to adjust the collected S-HyNic-VCAM1 antibody to 100μL to obtain S-HyNic-VCAM1 antibody solution;
[0160] (4) Covalent coupling of DNA1-S-4FB and S-HyNic-VCAM1 antibody:
[0161] ① Take 11 μL of the DNA1-S-4FB solution prepared in step (2) and 12 μL of 10×Turbolink Catalyst Buffer (Solulink, catalog number S-2006-105) and add them to 100 μL of the S-HyNic-VCAM1 antibody solution prepared in step (3), pipette and mix evenly, and shake at 400 rpm at 25°C for 2 h;
[0162] ② After the reaction is completed, the reaction system is transferred to a 50kDa ultrafiltration tube, 1×PBS (pH 7.4) is added to make the total volume 500μL, centrifuged at 13000g for 10min, the waste liquid is discarded, and this washing process is repeated 5 times; then the ultrafiltration tube is turned upside down in a new centrifuge tube, centrifuged at 1500g for 3min, and the collected DNA1-VCAM1 antibody is fixed to 100μL with 1×PBS (pH 7.4) to obtain the DNA1-VCAM1 antibody covalent conjugate.
[0163] In order to test whether DNA1 and VCAM1 antibody are successfully connected, the molecular weight of the DNA1-VCAM1 antibody covalent conjugate prepared in step 2 was detected by SDS-PAGE electrophoresis. The results are as follows: Figure 4 shown.
[0164] Depend on Figure 4It can be seen that compared with the band migration rate of VCAM1 antibody, the band migration rate of DNA1-VCAM1 antibody covalent conjugate is significantly slower, and the connection of DNA1 to VCAM1 antibody increases the molecular weight of VCAM1 antibody, indicating that DNA1 and VCAM1 antibody are successfully covalently coupled.
[0165] In order to evaluate whether the connection of DNA1 would affect the specificity of VCAM1 antibody, the binding specificity of the DNA1-VCAM1 antibody covalent conjugate prepared in step 2 was detected by flow cytometry. Figure 5 As shown; the control group was unmodified K562 cells or C166 cells.
[0166] Depend on Figure 5 It can be seen that the binding of VCAM1 antibody and DNA1-VCAM1 antibody covalent conjugate to K562 (not expressing VCAM1) is very weak, while the binding of VCAM1 antibody and DNA1-VCAM1 antibody covalent conjugate to C166 (overexpressing VCAM1) can be effectively bound, and there is no significant difference in the binding strength of VCAM1 antibody and DNA1-VCAM1 antibody covalent conjugate to C166, which indicates that the connection of DNA1 to VCAM1 antibody does not affect the specificity of VCAM1 antibody.
[0167] 3. Preparation of polydopamine and VCAM1 antibody engineered mesenchymal stem cells:
[0168] (1) The nucleotide sequence of DNA monomer 2 complementary to DNA monomer 1 is: 5'-TTTTTTTTTTTTTTTTTTTTGCTAATCGGTAAACAAAGGCTGC-3' (SEQ ID NO: 2), and a cholesterol group is connected to the 5' end; DNA monomer 2 is synthesized by Sangon Biotechnology (Shanghai) Co., Ltd., and DNA monomer 2 is referred to as DNA2 in subsequent steps;
[0169] (2) Take 1×10 6 The polydopamine surface-modified mesenchymal stem cells prepared in step 1 above were resuspended in 200 μL of 1×PBS (pH 7.4), and cholesterol-labeled DNA2 was added to make the final concentration of DNA2 1 μM. At the same time, 3 μL of the DNA1-VCAM1 antibody covalent conjugate prepared in step 2 above was added, and the mixture was mixed by pipetting to obtain a cell mixed solution;
[0170] (3) Transfer the cell mixture solution from step (2) to a shaking metal bath and shake at 500 rpm at 25°C for 30 min, mixing once every 5 min with a pipette;
[0171] (4) After the reaction is completed, 1 mL of 1× PBS (pH 7.4) is added to the cell mixture solution, centrifuged at 300 g for 5 min, the supernatant is removed, and the washing process is repeated twice to obtain mesenchymal stem cells engineered with polydopamine and VCAM1 antibodies.
[0172] In order to test whether the DNA-VCAM1 conjugate was successfully modified on the cell surface, the VCAM1 antibody (labeled with FITC) on the surface of the mesenchymal stem cells engineered with polydopamine and VCAM1 antibody prepared in step 3 was characterized by flow cytometry and laser confocal microscopy. The results were as follows: Figure 6 and Figure 7 shown.
[0173] Depend on Figure 6 It can be seen that the mesenchymal stem cells modified with polydopamine and VCAM1 antibody have obvious fluorescence signals compared with the control group (unmodified cells) and the polydopamine modified group (i.e., the cells prepared in step 1 of Example 1), indicating that VCAM1 antibody is successfully modified on the mesenchymal stem cells.
[0174] Depend on Figure 7 It can be seen that the FITC fluorescence signal is located on the surface of mesenchymal stem cells, which indicates that the VCAM1 antibody is successfully modified on the cell membrane of mesenchymal stem cells.
[0175] Example 2
[0176] This embodiment provides a stem cell engineering transformation method, and an engineered embryonic stem cell is prepared according to the method. The specific preparation steps are the same as those in Example 1.
[0177] The prepared polydopamine nanoparticles modified embryonic stem cells were characterized by scanning electron microscopy. Figure 8 The control group cells were unmodified embryonic stem cells.
[0178] Depend on Figure 8 It can be seen that the cell surface of the control group is relatively smooth, while the surface of the embryonic stem cells modified with polydopamine nanoparticles is rough, and obvious nanoparticles can be seen, indicating that the present invention successfully modifies the surface of embryonic stem cells with polydopamine.
[0179] In order to test whether the DNA-VCAM1 conjugate was successfully modified to the cell surface, the VCAM1 antibody (labeled with FITC) on the surface of embryonic stem cells engineered with polydopamine and VCAM1 antibody was characterized using laser confocal microscopy. Fig. 9 shown.
[0180] Depend on Fig. 9It can be seen that the FITC fluorescence signal is located on the surface of embryonic stem cells, which indicates that the VCAM1 antibody is successfully modified on the cell membrane of embryonic stem cells.
[0181] Test example
[0182] This test example tests the various characteristics and properties of the engineered mesenchymal stem cells prepared in Example 1. The specific test steps and results are as follows:
[0183] 1. Test the effect of surface modification on the activity of mesenchymal stem cells:
[0184] (1) Take 1×10 5 Unmodified mesenchymal stem cells (control group), 1×10 5 Polydopamine-modified mesenchymal stem cells (prepared in step 1 of Example 1) and 1×10 5 Each polydopamine-VCAM1 antibody-modified mesenchymal stem cell (prepared in step 3 of Example 1) was resuspended in 195 μL Annexin V-FITC conjugate solution (Beyotime, product number C1062S-2);
[0185] (2) Add 5 μL Annexin V-FITC (Beyotime, product number C1062S-1) to each group and mix well by gently pipetting;
[0186] (3) Add 10 μL of propidium iodide staining solution (Beyotime, product number C1062S-3) and mix gently by pipetting;
[0187] (4) Incubate at 25°C in the dark for 15 min, then place in an ice bath, gently pipetting 2 to 3 times during the incubation process;
[0188] (5) Flow cytometry test, the results are as follows Fig.10 shown.
[0189] Depend on Fig.10 It can be seen that there is no significant difference in the activity of mesenchymal stem cells modified with polydopamine and mesenchymal stem cells modified with polydopamine-VCAM1 antibody compared with unmodified mesenchymal stem cells, indicating that the polydopamine and VCAM1 antibody conjugate has almost no effect on the activity of mesenchymal stem cells when modified on the cell surface.
[0190] 2. Test the effect of surface modification on the migration ability of mesenchymal stem cells:
[0191] (1) 200 μL of unmodified mesenchymal stem cells (control group), polydopamine-modified mesenchymal stem cells (prepared in step 1 of Example 1), and polydopamine-VCAM1 antibody-modified mesenchymal stem cells (prepared in step 3 of Example 1) resuspended in serum-free DMEM were inoculated into the upper chambers of different Transwell chambers (Corning, 3422) in a 24-well plate, respectively, with a cell concentration of 2.5×10 5 / mL, add 700 μL of DMEM medium containing 10% serum into the lower chamber of the Transwell chamber;
[0192] (2) Place the 24-well plate in a cell culture incubator at 37°C and 5% CO2 for 12 h;
[0193] (3) Take out the chamber in the 24-well plate, discard the culture medium, and then immerse the chamber in PBS containing 4% paraformaldehyde for 15 min to fix the cells. After fixation, wash the chamber twice with 1× PBS;
[0194] (4) Add crystal violet staining solution to the chamber, immerse the upper and lower sides of the chamber bottom, and stain for 20 min. After staining, wash the chamber twice with 1× PBS and wipe the cells on the upper side of the chamber bottom with a cotton swab;
[0195] (5) Use a microscope to observe and photograph the cells on the bottom side of the chamber, and use ImageJ software to count and quantify the number of cells. The results are as follows: Fig.11 shown.
[0196] Depend on Fig.11 It can be seen that there is no significant difference in the number of migrating cells in the polydopamine modified group and the polydopamine-VCAM1 antibody modified group compared with the unmodified mesenchymal stem cells, indicating that the modification of the cell surface by the polydopamine and VCAM1 antibody conjugate has almost no effect on the migration ability of mesenchymal stem cells.
[0197] In addition, this test example also detected the effects of polydopamine modification and polydopamine and VCAM1 antibody modification on the paracrine secretion of mesenchymal stem cells. The specific steps are as follows:
[0198] Take 5×10 5 Unmodified mesenchymal stem cells (control group), 5×10 5 Polydopamine-modified mesenchymal stem cells (prepared in step 1 of Example 1) and 5×10 5The polydopamine-VCAM1 antibody-modified mesenchymal stem cells (prepared in step 3 of Example 1) were seeded in three culture dishes, and 8 mL of complete culture medium was added to each culture dish to allow the three groups of cells to adhere to the wall and grow for 3 days; after 3 days, the complete culture medium was removed, and 8 mL of serum-free culture medium was added to the three groups of cells, and the cells were cultured for another 3 days; after the serum-free culture medium culture was completed, the serum-free culture medium in the three groups of cells was collected; ELISA kits (Shanghai ELISA Biotechnology Co., Ltd., catalog numbers JLC3311, JLC3907, JLC3897, JLC3170 and JLC4130) were used to detect the concentrations of FGF2, VEGF, HGF, SDF-1 and TGF-β1 in the serum-free culture medium of the three groups, and the results were as follows: Fig.12 shown.
[0199] Depend on Fig.12 It can be seen that there is no significant difference in the concentration of various paracrine factors secreted by the control group cells, polydopamine modified group cells and polydopamine-VCAM1 antibody modified group cells, which indicates that polydopamine modification and polydopamine and VCAM1 antibody modification have no effect on the paracrine secretion of mesenchymal stem cells.
[0200] 3. Test the ability of polydopamine-modified mesenchymal stem cells to scavenge hydrogen peroxide:
[0201] (1) Three groups were set up: control group, control group + hydrogen peroxide, and polydopamine modified group + hydrogen peroxide. The control group was composed of unmodified mesenchymal stem cells, and the polydopamine modified group was composed of cells prepared in step 1 of Example 1. Each group contained 1×10 6 Mesenchymal stem cells were resuspended in 500 μL 1×PBS; the amount of hydrogen peroxide added was 30 wt % to make the final concentration of hydrogen peroxide 1 mM, and the mixture was gently pipetted and mixed;
[0202] (2) Incubate at room temperature for 1 h. After incubation, centrifuge at 300 g for 5 min, discard the supernatant, wash the cells once with 1× PBS, and resuspend the cells in 1 mL of 1× PBS;
[0203] (3) Add 1 μL of DCFH-DA probe (Beyotime, product number S0033S-1) to the cell suspension and incubate at 37°C for 20 min;
[0204] (4) After incubation, the cells were centrifuged at 300 g for 5 min, washed twice with 1× PBS, and resuspended in 1 mL of 1× PBS;
[0205] (5) Take 30 μL of the cell suspension obtained in step (4) and place it in a confocal dish. Use a laser confocal microscope to image the cells. The results are as follows: Fig.13 shown.
[0206] Depend on Fig.13 It can be seen that the intracellular reactive oxygen fluorescence intensity of the polydopamine modified group + hydrogen peroxide is significantly lower than that of the control group + hydrogen peroxide, which indicates that polydopamine modification can effectively improve the reactive oxygen scavenging ability of mesenchymal stem cells.
[0207] 4. CCK8 method to test the cell viability of engineered mesenchymal stem cells after hydrogen peroxide treatment:
[0208] (1) Unmodified mesenchymal stem cells (control group), polydopamine-modified mesenchymal stem cells (prepared in step 1 of Example 1), and polydopamine-VCAM1 antibody-modified mesenchymal stem cells (prepared in step 3 of Example 1) were resuspended in complete DMEM medium to obtain a cell concentration of 2×10 5 Cell suspension of 100 cells / mL;
[0209] (2) 100 μL of the cell suspension from each group was inoculated into each well of a 96-well plate, and each group of cells was inoculated into 9 replicate wells, for a total of 27 wells; the 9 replicate wells of each group of cells were then equally divided into 3 groups, namely, a control group without hydrogen peroxide addition, a low-concentration treatment group with a final hydrogen peroxide concentration of 400 μM, and a high-concentration treatment group with a final hydrogen peroxide concentration of 800 μM;
[0210] (3) Place the 96-well plate in a 37°C, 5% CO2 incubator and incubate for 2 h;
[0211] (4) After incubation, add 10 μL of CCK8 solution to each well and continue incubation for 2 h;
[0212] (5) Use an ELISA reader to measure the absorbance of each well of cells at 450 nm and calculate the cell viability. The results are as follows: Fig.14 shown.
[0213] Depend on Fig.14 It can be seen that after treatment with 400 μM and 800 μM hydrogen peroxide, the cell viability of mesenchymal stem cells modified with polydopamine or mesenchymal stem cells modified with polydopamine-VCAM1 antibody was significantly higher than that of unmodified mesenchymal stem cells, indicating that both polydopamine modification and polydopamine-VCAM1 antibody modification can effectively improve the survival rate of mesenchymal stem cells in a hydrogen peroxide microenvironment.
[0214] The three groups of cells treated with 800 μM hydrogen peroxide were stained with a live-dead staining kit and then imaged using laser confocal microscopy. The results are shown in Figure 2. Fig.15 shown.
[0215] Depend on Fig.15It can be seen that the number of living cells in the polydopamine-modified mesenchymal stem cells or the polydopamine-VCAM1 antibody-modified mesenchymal stem cells in the imaging field of view is significantly higher than that in the unmodified mesenchymal stem cell group, indicating that both polydopamine modification and polydopamine-VCAM1 antibody modification can effectively improve the survival of mesenchymal stem cells in the hydrogen peroxide microenvironment.
[0216] 5. Test the adhesion of engineered mesenchymal stem cells to vascular endothelial cells C166:
[0217] (1) Equal amounts of C166 cells were inoculated into three confocal microplates and cultured in a 37°C, 5% CO2 incubator. When the cells grew to a coverage rate of more than 85%, they could be used for subsequent experiments.
[0218] (2) Take 1×10 6 Unmodified mesenchymal stem cells (control group), polydopamine-modified mesenchymal stem cells (prepared in step 1 of Example 1), and polydopamine-VCAM1 antibody-modified mesenchymal stem cells (prepared in step 3 of Example 1) were resuspended in 1 mL 1×PBS;
[0219] (3) Add 1 μL of Calcein AM (Beyotime, product number C2015S-1) to each tube, mix well by pipetting, and place in a 37°C incubator for staining for 40 min;
[0220] (4) After staining, centrifuge at 300 g for 5 min, remove the supernatant, wash the cells twice with 1× PBS, and finally resuspend in 1 mL of 1× PBS;
[0221] (5) The cell suspension was added to different confocal microplates seeded with C166 cells, and then the microplates were transferred to a 37°C incubator and incubated for 40 min;
[0222] (6) After incubation, remove the cell suspension in the dish and gently wash the dish three times with 1× PBS;
[0223] (7) Use laser confocal microscopy to observe the cells adhered to the dish and take pictures. Use ImageJ to quantify the number of adhered cells. The results are as follows: Fig.16 shown.
[0224] Depend on Fig.16 It can be seen that the number of mesenchymal stem cells modified with polydopamine and VCAM1 antibody adhering to C166 cells is about 4 times that of unmodified mesenchymal stem cells or mesenchymal stem cells modified with polydopamine, indicating that modification with VCAM1 antibody can significantly improve the adhesion ability of mesenchymal stem cells to vascular endothelial cells C166.
[0225] 6. Testing the retention and survival of engineered mesenchymal stem cells in a rat myocardial infarction model:
[0226] (1) Construction of rat myocardial infarction model:
[0227] The construction process of the rat myocardial infarction model is as follows Fig.17 As shown, the specific steps are as follows:
[0228] A male SD rat weighing about 250 g was selected, and 45 mg / kg of sodium pentobarbital anesthetic was injected intraperitoneally. After the rat was anesthetized, its limbs were fixed, and then an 18G indwelling needle was inserted into the rat's trachea. The indwelling needle was connected to a ventilator, and the ventilator was turned on. The tidal volume of the ventilator was set to 6.0 mL, the respiratory ratio was set to 5:4, and the respiratory rate was set to 80 times / min. The rat's chest cavity was opened to expose the heart, and the rat's left anterior descending coronary artery was ligated with 5-0 silk thread. The ligation site was 2 to 3 mm below the pulmonary artery cone and the left atrial appendage. After the ligation was completed, mesenchymal stem cells could be injected.
[0229] (2) Intramyocardial injection of engineered mesenchymal stem cells:
[0230] ① The mesenchymal stem cells used in this part are all SD rat bone marrow-derived mesenchymal stem cells expressing luciferase (purchased from Nanjing Wan Muchun Co., Ltd.), and then polydopamine-modified mesenchymal stem cells and polydopamine-VCAM1 antibody-modified mesenchymal stem cells are prepared according to the engineering transformation method provided in Example 1;
[0231] ②1×10 6 Unmodified mesenchymal stem cells, 1×10 6 Polydopamine-modified mesenchymal stem cells and 1×10 6 Each polydopamine-VCAM1 antibody-modified mesenchymal stem cell was resuspended in 100 μL 1×PBS; 100 μL of the cell suspension was injected into five sites at the border of myocardial infarction using an insulin needle, with 20 μL injected into each site; then the rat's chest cavity was closed, the air in the chest cavity was exhausted, and the skin and flesh were sutured with 5-0 silk sutures;
[0232] (3) Bioluminescence imaging:
[0233] D-luciferin potassium salt (Aladdin) was dissolved in sterile 1×PBS to a final concentration of 15 mg / mL. On the third day after the injection of mesenchymal stem cells, the rats were anesthetized by intraperitoneal injection of sodium pentobarbital. After the rats were anesthetized, 2.5 mL of D-luciferin potassium salt solution was intraperitoneally injected into each rat. The rats were then placed in a small animal in vivo imaging device for imaging. The results are shown in Figure 2. Fig.18 shown.
[0234] Depend on Fig.18 It can be seen that the bioluminescent signal intensity of the polydopamine modified group was about 4 times that of the control group; the bioluminescent signal intensity of the polydopamine-VCAM1 antibody modified group was about 8 times that of the control group and about 2 times that of the polydopamine modified group, which indicates that polydopamine modification can effectively improve the survival of mesenchymal stem cells in the infarcted myocardium; compared with only polydopamine modification, modification of polydopamine and VCAM1 antibody can further promote the retention and survival of mesenchymal stem cells in damaged tissues.
[0235] 7. Test the repair effect of engineered mesenchymal stem cells on myocardial infarction in rats:
[0236] (1) Construction of rat myocardial infarction model and experimental grouping:
[0237] A rat myocardial infarction model was established according to the method described in step (1) of Part 6 of this test example. The experiment was divided into five groups, namely a sham operation group (without coronary artery ligation, and the rest of the steps were the same), a PBS group, a control group, a polydopamine-modified group, and a polydopamine-modified-VCAM1 antibody-modified group, with five rats in each group;
[0238] (2) Intramyocardial injection of engineered mesenchymal stem cells:
[0239] The mesenchymal stem cells used here are SD rat bone marrow-derived mesenchymal stem cells (purchased from Synbio (Shanghai) Biotechnology Co., Ltd.), and the cells were injected into the myocardium according to the method described in step (2) of Part 6 of this experimental example;
[0240] Among them, the sham operation group was not injected with cells and PBS, the PBS group was injected with 100 μL 1×PBS intramyocardially, the control group was injected with unmodified mesenchymal stem cells, the polydopamine modified group was injected with mesenchymal stem cells modified with only polydopamine (prepared according to the method of step 1 in Example 1), and the polydopamine modified-VCAM1 antibody modified group was injected with mesenchymal stem cells modified with polydopamine-VCAM1 antibody (prepared according to the method of step 3 in Example 1);
[0241] (3) Small animal ultrasound detection of rat cardiac function:
[0242] After 4 weeks of treatment, the rats were placed in an anesthesia machine and anesthetized with isoflurane. The Vevo3100 imaging system was used for echocardiography. The left ventricular ejection fraction (LVEF) and fractional shortening (FS) were calculated based on the M-mode ultrasound imaging. The calculation formula was: left ventricular ejection fraction = (left ventricular end-diastolic volume - left ventricular end-systolic volume) / left ventricular end-diastolic volume × 100%, fractional shortening = (left ventricular diastolic diameter - left ventricular systolic diameter) / left ventricular diastolic diameter × 100%. The results are shown in Figure 2. Fig.19 As shown;
[0243] (4) Pathological section detection of the repair effect of rat infarcted myocardium:
[0244] After 4 weeks of treatment, all rats were euthanized, and the hearts of all rats were removed. The hearts were fixed with paraformaldehyde, dehydrated with gradient alcohol, and then embedded in paraffin to form myocardial tissue wax blocks. The hearts were cross-sectioned using a paraffin slicer with a slice thickness of 5 μm; the obtained heart slices were dewaxed with xylene and then rehydrated. The normal myocardium and fibrotic myocardium were stained using the Masson's trichrome staining kit (Solabo). The stained slices were finally sealed with neutral resin and read using a pathological slice scanner. The results are shown in the figure. Fig. 20 shown.
[0245] Depend on Fig.19 It can be seen that after 4 weeks of treatment, the left ventricular ejection fractions of the sham operation group, PBS group, control group, polydopamine modified group and polydopamine-VCAM1 antibody modified group were 86.64%, 37.55%, 51.01%, 63.53% and 75.61%, respectively, which indicates that compared with the sham operation group, the PBS group, control group, polydopamine modified group and polydopamine-VCAM1 antibody modified group have gradually enhanced recovery effects on the cardiac function of rat infarcted heart.
[0246] Depend on Fig. 20 It can be seen that compared with the sham operation group, the infarct size of the PBS group, control group, polydopamine modified group, and polydopamine-VCAM1 antibody modified group gradually decreased, while the left ventricular wall thickness gradually increased, which indicates that the repair effect increases successively, and the polydopamine-VCAM1 antibody modified group has the best therapeutic effect.
[0247] In addition, the tissue reactive oxygen species probe DHE was used to detect the reactive oxygen species level in the infarcted myocardial tissue at 3 days after treatment. Fig.21 shown.
[0248] Depend on Fig.21 It can be seen that compared with the sham operation group, the levels of reactive oxygen species in the myocardial tissue of the polydopamine modified group and the polydopamine and VCAM1 antibody modified group were lower, indicating that polydopamine modification can effectively improve the reactive oxygen species scavenging ability of mesenchymal stem cells.
[0249] After 4 weeks of treatment, immunofluorescence staining was performed on the myocardial tissues of each group. Fig. 22 and 23 As shown. Figures 22-23It can be seen that compared with the sham operation group, the number of CD31 and α-SMA positive blood vessels in the PBS group, control group, polydopamine modified group, polydopamine and VCAM1 antibody modified group increased in turn, indicating that the effect of promoting angiogenesis in the PBS group, control group, polydopamine modified group, polydopamine and VCAM1 antibody modified group was enhanced in turn. The main reason for the low retention rate of stem cells in the damaged tissue site is that the cells need to be expanded and cultured in vitro before being transplanted into the body. During the in vitro expansion and culture process, stem cells will lose key cell surface biomolecules such as adhesion molecules. In addition, the damaged tissue site is in a hypoxic state and there is an excessive amount of reactive oxygen. This harsh microenvironment is the main cause of the death of transplanted stem cells. At present, some researchers have transformed stem cells through genetic engineering methods to overexpress related adhesion molecules on their cell surface, which to a certain extent improves the retention of cells at the site of tissue damage, but this method is complicated to operate, inefficient, time-consuming, costly and has safety risks. In addition, studies have reported that the use of hydrogel encapsulation of stem cells can increase cell retention time and survival rate, but too large an encapsulation volume is not conducive to the transmission of substances, and is likely to cause problems such as metabolite accumulation, insufficient supply of nutrients, and hypoxia, and large-size gel encapsulation is only suitable for local administration, which limits the cell administration route. Microgels can achieve single-cell encapsulation of stem cells. This encapsulation system will not limit the delivery route of cells, and can also effectively improve the survival rate of stem cells. However, microgel encapsulation will shield important biological functional molecules on the surface of cells, and may also affect the exchange of nutrients between cells and the outside world, affecting cell function. In order to overcome the shortcomings of the above method, the present invention provides a stem cell engineering transformation method, which is simple and safe to operate and has little effect on cells. The engineered stem cells prepared can be more efficiently retained and survived in damaged tissues and repair damaged tissues compared to unmodified stem cells.
[0250] The present invention also verified the above experimental results in induced pluripotent stem cells and cardiac stem cells, and the results confirmed that the same effect as mesenchymal stem cells can be achieved, indicating that the stem cell engineering transformation method provided by the present invention is applicable to a variety of stem cell types.
[0251] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A double-stranded DNA fragment, characterized in that The double-stranded DNA fragment includes a DNA monomer 1 and a DNA monomer 2; the nucleotide sequence of the DNA monomer 1 is shown in SEQ ID NO: 1; the nucleotide sequence of the DNA monomer 2 is shown in SEQ ID NO: 2; the nucleotide sequences of the DNA monomer 1 and the DNA monomer 2 are complementary.
2. The double-stranded DNA fragment according to claim 1, characterized in that The 5' end of the nucleotide sequence of the DNA monomer 1 is connected to an NH2C6 group; And / or, a cholesterol group is connected to the 5' end of the nucleotide sequence of the DNA monomer 2.
3. A VCAM1 antibody conjugate, characterized in that: The VCAM1 antibody conjugate comprises a VCAM1 antibody and a polymer connected by a covalent bond; the polymer comprises at least one of the DNA fragment according to claim 1 or 2, DSPE-PEG-NHS, DMPE-PEG-NHS and DOPE-PEG-NHS.
4. A cell, characterized in that The cell surface is modified with: the VCAM1 antibody conjugate and polydopamine nanoparticles as claimed in claim 3; Preferably, the polydopamine nanoparticles are dopamine monomers in a Ca-containing 2+ Polymerized in an alkaline buffer solution; More preferably, the alkaline buffer comprises Tris-HCl buffer; More preferably, the Ca in the alkaline buffer is 2+ The content is 0.11-4.44wt%; More preferably, the concentration of the dopamine monomer in the alkaline buffer is 0.05-5 mg / mL.
5. A kit, characterized in that: The kit comprises: (1) the VCAM1 antibody conjugate according to claim 3; and (2) The polydopamine nanoparticles as described in claim 4.
6. Use of the double-stranded DNA fragment according to claim 1 or 2, the VCAM1 antibody conjugate according to claim 3, the polydopamine nanoparticles according to claim 4 or the kit according to claim 5 in cell engineering transformation.
7. A cell engineering transformation method, characterized in that: The cell engineering transformation method comprises the following steps: S1: mixing the cells to be modified with the dopamine monomers described in claim 4 to react and obtain cells modified with polydopamine nanoparticles; S2: Mixing the cells modified with the polydopamine nanoparticles described in step S1 with the VCAM1 antibody conjugate described in claim 3, and reacting to obtain engineered cells.
8. The cell engineering transformation method according to claim 7, characterized in that: The final concentration of the dopamine monomer in step S1 is 0.05-5 mg / mL; And / or, the cells to be transformed in step S1 are mixed with dopamine monomers in a Ca-containing 2+ react in an alkaline buffer.
9. The cell engineering transformation method according to claim 7, characterized in that: The reaction conditions in step S1 are 20-37° C. for 5-15 min; And / or, the reaction conditions in step S2 are 20-37° C. for 15-60 min.
10. Use of the cell according to claim 4 or the cell engineering transformation method according to any one of claims 7 to 9 in at least one of (1) to (3): (1) Preparation of products for tissue repair; (2) Preparation of products for enhancing the retention of cells in damaged tissues; (3) Prepare products for enhancing the survival ability of cells in damaged tissues.
Citation Information
Patent Citations
Construction method for high-throughput micro-fluidic chip detecting system
CN102901830A
Method for cell surface functional coating modifying
CN107904190A
Nucleic acid coded CAR-T cells, and preparation method and application thereof
CN111378622A
Living cell surface functionalization based on dopamine polymerization and application
CN114807108A
Mesenchymal stem cell engineering transformation method based on protein multimer and application of mesenchymal stem cell engineering transformation method
CN116120453A
Cited By
Mesenchymal stem cell transformation method based on bispecific antibody and application of mesenchymal stem cell transformation method in treatment of inflammatory bowel disease
CN120463813A
